[인문]Novartis Case Study
- 최초 등록일
- 2007.07.27
- 최종 저작일
- 2007.07
- 9페이지/ MS 워드
- 가격 2,000원
소개글
Novartis: The Challenge of Success
로 Havard Business Review 에 나온 사례분석을
Case Study 한것입니다.
목차
- Summary of the Case
- Lessons to Learn (Case Analysis)
본문내용
- Summary of the Case
1. Gleevec Launch
On 10 May 2001, Gleevec received FDA approval for the treatment of patients with chronic myelogenous leukemia (CML) in blast crisis, accelerated or chronic phase after interferon-alfa therapy has failed. In June 2001, Gleevec received its first EU approval in Switzerland for the same indications: Switzerland was used as a reference state for mutual recognition. The initially approved indications represent only a relatively small proportion of CML patients. However, off-label usage in the first line setting is believed to be partly responsible for the drug’s sales in 2002. In December 2002, Gleevec received approval in both the US and EU for first line treatment of CML, increasing the potential market size and driving sales growth in 2003.
참고 자료
없음